Overall, these data suggest that MyD88-dependent signaling through TLR2, TLR4, TLR7, and TLR9 mediates MS progression, while TLR3 activation protects from disease by activation of innate immunity [68]. Here, TLR9 is linked to myeloid sarcoma.